ReviewExpert reviews in molecular medicine2025
An Update on Clinical and Pathogenic Spectra of Leishmaniasis.
Review in Expert reviews in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of Microbiome and Bacterial Biofilms in the Pathogenesis of Cutaneous Leishmaniasis.Acta parasitologica · 2026Review
- TargetingMetabolites · 2026Article
- Antileishmanial Activity ofMolecules (Basel, Switzerland) · 2026Article
- Analytical and clinical performance of in-house and commercial real-time PCR assays for diagnosingJournal of clinical microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Leishmaniasis, classified as a neglected tropical disease, exerts its impact on millions globally. Its clinical spectrum encompasses diverse forms, from benign self-resolving skin lesions (cutaneous leishmaniasis) to life-threatening visceral infections (visceral leishmaniasis or kala-azar). This review aims to comprehensively explore the spectrum of the disease as an outcome of often-overlooked parasite variants. Additionally, it addresses the emerging challenges faced in the pursuit towards disease elimination. The evolving landscape of leishmaniasis demands the development of molecular surveillance tools to detect the heterogeneous parasite strains that contribute to the emergence of new endemic foci. Such surveillance poses formidable challenges to current elimination strategies. As the disease landscape continues to evolve, understanding the molecular intricacies of causative parasite strains becomes paramount. This knowledge not only aids the understanding of the basis of emerging/shifting endemic areas but also facilitates the search for and the design of targeted interventions. In this context, this review will navigate through the dynamic terrain of leishmaniasis, the various causative species of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.